| Literature DB >> 35785292 |
Indresh Kumar1, Rashmi Nayak2, Lal Babu Chaudhary2, Vashist Narayan Pandey3, Sheo K Mishra4, Narendra Kumar Singh1, Abhishek Srivastava5, Surendra Prasad6, Radhey Mohan Naik1.
Abstract
In the present work, iron nanoparticles were synthesized in the α-Fe2O3 phase with the reduction of potassium hexachloroferrate(III) by using l-ascorbic acid as a reducing agent in the presence of an amphiphilic non-ionic polyethylene glycol surfactant in an aqueous solution. The synthesized α-Fe2O3 NPs were characterized by powder X-ray diffraction, field emission scanning electron microscopy, transmission electron microscopy, atomic force microscopy, dynamic light scattering, energy dispersive X-ray spectroscopy, Fourier transform infrared spectroscopy, and ultraviolet-visible spectrophotometry. The powder X-ray diffraction analysis result confirmed the formation of α-Fe2O3 NPs, and the average crystallite size was found to be 45 nm. The other morphological studies suggested that α-Fe2O3 NPs were predominantly spherical in shape with a diameter ranges from 40 to 60 nm. The dynamic light scattering analysis revealed the zeta potential of α-Fe2O3 NPs as -28 ± 18 mV at maximum stability. The ultraviolet-visible spectrophotometry analysis shows an absorption peak at 394 nm, which is attributed to their surface plasmon vibration. The cytotoxicity test of synthesized α-Fe2O3 NPs was investigated against human carcinoma A549 lung cancer cells, and the biological adaptability exhibited by α-Fe2O3 NPs has opened a pathway to biomedical applications in the drug delivery system. Our investigation confirmed that l-ascorbic acid-coated α-Fe2O3 NPs with calculated IC50 ≤ 30 μg/mL are the best suited as an anticancer agent, showing the promising application in the treatment of carcinoma A549 lung cancer cells.Entities:
Year: 2022 PMID: 35785292 PMCID: PMC9245107 DOI: 10.1021/acsomega.2c02083
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Systematic illustration of the synthesis of α-Fe2O3 NPs.
Scheme 1Scheme for the Synthesis of α-Fe2O3 NPs
Figure 2(a) Powder X-ray diffraction analysis and (b) Williamson-Hall plot of α-Fe2O3 NPs.
Figure 3(a–d) FE-SEM images and (e) EDX profile of α-Fe2O3 NPs.
Figure 4Transmission electron microscopy (TEM) image of α-Fe2O3 NPs.
Figure 5Atomic force microscopy (AFM) images: (a) 2-D and (b) 3-D surface morphological analysis of synthesized α-Fe2O3 NPs.
Figure 6(a) Dynamic light scattering (DLS) analysis for particle size and distribution (b) zeta potential analysis of α-Fe2O3 NPs.
Figure 7UV–visible absorption spectra of α-Fe2O3 NPs.
Figure 8FTIR spectra of α-Fe2O3 NPs.
Figure 9(a) Cell viability of α-Fe2O3 NPs, (b) effect of dose of α-Fe2O3 NPs and Adriamycin on human A549 lung cancer cells, and (c) microscopic images of α-Fe2O3 NPs against A549 lung cancer cell lines (copyright 2022 Abbas Ali Mehdi).